We commend Kalman et al. 1 for their study on the cardiovascular effects of an herbal ephedra-caffeine weight loss product, because the occurrence of adverse events associated with ephedra ingestion has not been adequately addressed in the literature. However, to definitively answer research questions regarding the cardiovascular effects of ephedra ingestion, we believe that future studies should incorporate the following suggestions: (1) Assess subjects at more than a single time point. Kalman et al 1 compared
presupplementation cardiovascular parameters and postsupplementation cardiovascular parameters on different days. Given the large within subject variability in heart rate and blood pressure throughout a typical day, it may be difficult to detect changes based on a single time measurement over a several week period. (2) Determine the time points for cardiovascular assessment based on drug absorption. In one study, the maximal increase in systolic blood pressure (14 mm Hg) occurred 90 min after ephedra ingestion, while the maximum change in heart rate (15 beats min
À1
) occurred 6 h following ingestion. 2 Negative effects of ephedra/ephedrine supplements on blood pressure and heart rate have been reported with higher doses 3,4 and lower doses 2 than administered by Kalman et al. 1 These discrepancies further demonstrate that timing of dose compared to assessment of cardiovascular function is crucial. (3) Rigorous control over the subject-related factors that are known to influence drug metabolism and disposition (ethnicity, gender, physical activity and fitness level, body size and composition, age, caffeine intake, recent food intake, comedication). For instance, caffeine intake was not reported and appears to have been unregulated in both groups (subjects were allowed to consume up to three cups of coffee or caffeine equivalent per day during the study). (4) An analysis of supplement content. The ephedrine content of Ephedra plants can vary widely, 5 resulting in as much as 100% variability in ephedrine content between lots of a given supplement. 6 Given the reported poor standardization of ephedra products, it seems prudent to provide an analysis of supplement content. There are many cases of persons suffering severe adverse events related to the use of ephedra/ephedrine ingestion who apparently were not at increased risk for undesirable effects. 7, 8 Given how rapidly studies unable to demonstrate adverse events associated with nutritional supplements are assimilated and publicized by the nutritional supplement industry and magazines, we believe that research on nutritional supplements should be subject to the same rigorous standards as drug research. Kalman et al 1 present
interesting data on ephedra and caffeine ingestion in a relatively small sample of healthy overweight adults. This study adds to the growing body of literature of the cardiovascular effects associated with ephedra ingestion, and we hope others will use it to inspire research that includes the controls suggested above. Note added in press: Since this letter was accepted for publication ephedra has been removed from the market in the United States, and has left a gap in the dietary supplement industry in the area of weight loss products. Synephrine, found in citrus aurantium (Bitter Orange), is rapidly filling this gap and is widely used in ''ephedra-free'' products. 9 Synephrine is an alpha-agonist related to more commonly used alpha-adrenergic agonists pseudoephedrine and phenylpropanolamine (the active ingredient in Dexatrim s that was removed from market in 2000). The suggestions we make in this letter for studying the cardiovascular effects of nutritional supplements such as ephedra, and now synephrine, will continue to be relevant as long as people are interested in using weight loss supplements.
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